• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Combo drugs: latest trend in local pharmaceuticals

    KOREAMED

    U.S. FDA Approves GATTEX® for Children 1Y Age&Older With Short Bowel Syndrome

    PR NEWSWIRE

    Shire Moves to Protect Gattex From Par Generic Challenge

    BLOOMBERG

    Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.

    PATENT LITIGATION

    SMC endorses five new therapies for NHS Scotland

    PHARMA TIMES

    FDA Confirms Paragraph IV Patent Challenge of Gattex (Teduglutide) Injection

    FDA

    NICE turns down Shire’s Revestive for bowel condition

    PHARMA TIMES

    Gattex (Teduglutide): Shire-NPS Pharma v. AmbioPharm & Par Pharmaceutical

    PATENT LITIGATION

    Shire Receives Extension of Market Authorization in Europe for Revestive

    PR NEWSWIRE

    Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide)

    PR NEWS WIRE

    Drugmakers to Congress: You want patent reforms? Stop pharma challenger Bass

    FIERCE PHARMA

    Shire`s Lialda, Gattex are hedge funder`s latest patent targets

    FIERCE PHARMA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.